294 Comparison of preclinical efficacy between CD19 CAR-T and CD3×CD19 bispecific antibody (blinatumomab)

• Jun Huang,
• Ronghua Zhang,
• Xiangnan Qiang,
• Zhixiang Zhang,
• Ting Ni,
• Chenhui He,
• Zhifeng Zhao,
• Jingwei Huang,
• Xiangyi Wang

Affiliations

Jun Huang

2Department of Cardiovascular Medicine, Xianning Centre Hospital, 228 Jingui Road, Xianning 437100, China

Ronghua Zhang

WXi ApTec, Shanghai, China

Xiangnan Qiang

3WuXi AppTec, Cambridge, MA, USA

Zhixiang Zhang

1WuXi AppTec, Shanghai, China

Ting Ni

1WuXi AppTec, Suzhou, Jiangsu, China

Chenhui He

3 WuXi AppTec, Nantong, Jiangsu, China

Zhifeng Zhao

3 WuXi AppTec, Nantong, Jiangsu, China

Jingwei Huang

2Wuxi App Tec, Shanghai, China

Xiangyi Wang

2Wuxi App Tec, Shanghai, China